192945-56-5

Usage

Uses

Used in Pharmaceutical Synthesis:
1H-INDAZOLE-6-CARBOXYLIC ACID,3-BROMO-,METHYL ESTER is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its structural versatility and pharmaceutical properties make it a valuable component in the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1H-INDAZOLE-6-CARBOXYLIC ACID,3-BROMO-,METHYL ESTER is utilized as a key intermediate in the production of biologically active compounds. Its unique structure allows for the exploration of new chemical entities with potential therapeutic applications.
Used in Drug Discovery Research:
1H-INDAZOLE-6-CARBOXYLIC ACID,3-BROMO-,METHYL ESTER is employed in drug discovery research to identify and develop new chemical entities with potential pharmaceutical applications. Its presence as an intermediate in the synthesis of biologically active compounds contributes to the advancement of novel drug candidates.
Used in Chemical Intermediates Production:
As an important intermediate, 1H-INDAZOLE-6-CARBOXYLIC ACID,3-BROMO-,METHYL ESTER is used in the production of various chemical intermediates that are essential for the synthesis of pharmaceuticals and other organic compounds. Its role in this process is crucial for the development of new and innovative chemical products.

InChI:InChI=1/C9H7BrN2O2/c1-14-9(13)5-2-3-6-7(4-5)11-12-8(6)10/h2-4H,1H3,(H,11,12)

Upstream product

• 170487-40-8 1H-indazole-6-carboxylic acid methyl ester 

Downstream Products

• 192945-57-6 methyl 3-bromo-1-methyl-1H-indazole-6-carboxylate 
• 1434142-10-5 methyl 3-bromo-2-methyl-2H-indazole-6-carboxylate 

Relevant academic research and scientific papers

Sodium channel blockers (by machine translation)

The invention belongs to the field of medicines, and particularly relates to a compound shown as a formula (I). A pharmaceutical composition comprising the compound, a pharmaceutically acceptable salt, a solvate or an isomer thereof, a pharmaceutically ac

P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor s

Compounds as syk kinase inhibitors

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase.

Integrin antagonists

This invention relates to novel heterocycles which are useful as antagonists of the αvβ3 integrin, the α2bβ3 integrin, and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Integrin receptor antagonists

This invention relates to novel heterocycles including 3-?1-?3-(imidazolin-2-ylamino)propyl!indazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)propionic acid, which are useful as antagonists of the αv β3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.